Journal of Clinical Oncology

Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.

Journal of Clinical Oncology

Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H. Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman

Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.

Journal of Clinical Oncology

Alexandra Thomas, Denise M. Wolf, Ronald Balassanian, Yunn-Yi Chen, Julia Ye, Poonam Vohra, Evin H Gulbahce, Alexander D. Borowsky, Lamorna Brown Swigart, Gillian L. Hirst, Sara Venters, Rita Nanda, Rebecca Arielle Shatsky, Ralph D'Agostino, Rita A. Mukhtar, Sarah Hatcher, Christina Yau, Angela DeMichele, Laura van 't Veer, Laura Esserman

Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.

Journal of Clinical Oncology

Roberto Antonio Leon-Ferre, Katrina Dimitroff, Christina Yau, Karthik Giridhar, Rita A. Mukhtar, Gillian L. Hirst, Nola Hylton, W. Fraser Fraser Symmans, Matthew P. Goetz, Laura Esserman, Judy Caroline Boughey

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.

Journal of Clinical Oncology

Erin Frances Cobain, Lajos Pusztai, Cathy Lynne Graham, Pat W. Whitworth, Peter D. Beitsch, Cynthia R. C. Osborne, Rakhshanda Layeequr Rahman, Nathalie MCDOWELL Johnson, Adam Brufsky, Reshma L. Mahtani, VK Gadi, Kent Hoskins, Hannah M. Linden, Rita A. Mukhtar, Laura Esserman, Josien Haan, Katie Quinn, Andrea Menicucci, M. William Audeh, Joyce O'Shaughnessy

I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).

Journal of Clinical Oncology

Amy Jo Chien, Rita A. Mukhtar, Karthik Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Christos Vaklavas, Anthony D. Elias, Mei Wei, Matthew P. Goetz, Laura van 't Veer, Silver Alkhafaji, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology

Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman

Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.

Journal of Clinical Oncology

Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, Amy Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar

Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.

Journal of Clinical Oncology

Ruby Guo, Case E. Brabham, Kelly Fahrner-Scott, Mary Kathryn Abel, Jasmine Wong, Michael Alvarado, Laura Esserman, Cheryl Ann Ewing, Rita A. Mukhtar

Breast tumor location in BRCA mutation carriers and implications for prevention.

Journal of Clinical Oncology

Ava Hosseini, Laura Esserman, Anne M. Wallace, Amal Khoury, Alfred Au, Rita Mukhtar

Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.

Journal of Clinical Oncology

R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman

Pages